Your browser doesn't support javascript.
loading
[HIV seroprevalence among drug users in Togo]. / Séroprévalence du VIH chez les usagers de drogues au Togo.
Ekouevi, Didier K; Coffie, Patrick A; Salou, Mounerou; Kariyiare, Benjamin G; Dagnra, Anoumou C; Tchounga, Boris; Prince-Davi, Mireille; Becquet, Renaud; Pitche, Vincent P.
Afiliación
  • Ekouevi DK; Département des Sciences Fondamentales et Santé Publique, Faculté Mixte de Médecine et de Pharmacie, Université de Lomé, Togo.
  • Coffie PA; Programme PAC-CI, CHU de Treichville, Abidjan, Côte d'Ivoire.
  • Salou M; Département des Sciences Fondamentales et Santé Publique, Faculté Mixte de Médecine et de Pharmacie, Université de Lomé, Togo.
  • Kariyiare BG; Centre Africain de Recherche en Epidémiologie et Santé Publique, Lomé, Togo.
  • Dagnra AC; Département des Sciences Fondamentales et Santé Publique, Faculté Mixte de Médecine et de Pharmacie, Université de Lomé, Togo.
  • Tchounga B; Programme PAC-CI, CHU de Treichville, Abidjan, Côte d'Ivoire.
  • Prince-Davi M; Département des Sciences Fondamentales et Santé Publique, Faculté Mixte de Médecine et de Pharmacie, Université de Lomé, Togo.
  • Becquet R; INSERM, Centre INSERM U897, Epidémiologie et Bio-statistique, Bordeaux, France.
  • Pitche VP; Programme National de Lutte contre le Sida, Ministère de la santé, Lomé, Togo.
Sante Publique ; 25(4): 491-8, 2013.
Article en Fr | MEDLINE | ID: mdl-24404731
ABSTRACT
CONTEXT In the context of implementing a serological and behavioural surveillance system among drugs users, this study estimated the prevalence of HIV infection and related risk behaviours among drug users (DUs) in Togo.

METHOD:

A cross-sectional study was conducted among DUs in Togo from November 2011 to January 2012. This study involved all DUs regardless of the type of drug and the mode of consumption, over the age of 18 years, who had lived in Togo for at least 3 months. Behavioural data were collected by face-to-face interviews and serum was obtained for HIV antibody testing. HIV prevalence was estimated together with its 95% confidence interval (CI). Univariate and then multivariate analyses were performed to study the factors associated with HIV prevalence.

RESULTS:

A total of 387 DUs participated in the survey and 235 (60.7%) of them were enrolled in Lomé, the country's capital. The median age of DUs was 32 years with an interquartile range of [25-39 years] and 10 (2.6%) were women. The mode of drug consumption was smoking or inhaling drugs in 92.8% of cases and 2.8% of DUs used drugs by injection. HIV testing was accepted in 98.4% of cases. The estimated HIV prevalence among drugs users was 5.5%, (95% CI, 3.2-7.8%).

CONCLUSION:

This study, the first to be conducted among DUs in Togo, found an HIV prevalence of 5.5%, which is higher than the HIV prevalence in the general population (3.2% in 2010). Specific care of DUs is essential in order to reduce HIV prevalence in Togo.
Asunto(s)
Buscar en Google
Banco de datos: MEDLINE Asunto principal: Infecciones por VIH / Seroprevalencia de VIH / Consumidores de Drogas Tipo de estudio: Diagnostic_studies / Observational_studies / Prevalence_studies / Qualitative_research / Risk_factors_studies Límite: Adult / Female / Humans / Male País/Región como asunto: Africa Idioma: Fr Año: 2013 Tipo del documento: Article
Buscar en Google
Banco de datos: MEDLINE Asunto principal: Infecciones por VIH / Seroprevalencia de VIH / Consumidores de Drogas Tipo de estudio: Diagnostic_studies / Observational_studies / Prevalence_studies / Qualitative_research / Risk_factors_studies Límite: Adult / Female / Humans / Male País/Región como asunto: Africa Idioma: Fr Año: 2013 Tipo del documento: Article